Navigation Links
Scientists create humanized mouse model for hepatitis C

Scientists at Rockefeller University and The Scripps Research Institute have developed the first genetically humanized mouse model for hepatitis C, an achievement that will enable researchers to test molecules that block entry of the hepatitis C virus into cells as well as potential vaccine candidates. The finding is reported in the June 9 issue of the journal Nature.

While the hepatitis C virus can infect chimpanzees and humans, scientists have been unable to study the progression of the virus' life cycle or possible treatments in small animal models. The new mouse model is the first to be developed with a fully functioning immune system.

"Our genetically humanized mouse model for hepatitis C will allow us to gain deeper insights in the biology of this important pathogen," says senior author Alexander Ploss, a research assistant professor at Rockefeller. "This robust small animal model also has the potential to serve a critical role in testing and prioritizing drug and vaccine candidates. Results from these tests can potentially guide more expensive pre-clinical and clinical studies in higher order organisms, including humans."

The development of this mouse model is the culmination of several years of research by scientists in the laboratory of Charles M. Rice and other research groups. In 2006, Rice and his colleagues were the first to successfully create a strain of hepatitis C in the laboratory, which can efficiently be grown in the laboratory, and is also infectious in animals. More recently, Rice, Ploss and their colleagues discovered that hepatitis C virus infection requires previously identified CD81 and scavenger receptor type B class I, as well as two tight junction molecules, claudin 1 and occludin. The Rockefeller researchers showed that human CD81 and occludin were required for hepatitis C virus to enter mouse cells.

In the new study, the Rockefeller researchers and colleagues at The Scripps Research Institute tested whether introducing some of these previously identified human genes into mice would allow them to infect the animals with the hepatitis C virus. The researchers compared two groups of mice: one group expressed two genes, CD81 and occludin, while mice in the second group were normal. They found that expression of human CD81 and human occludin in the mouse liver rendered the animals susceptible to HCV infection. Ploss and his colleagues also developed a novel reporter system, which allowed them to sensitively detect HCV infection in living animals.

"We have established a precedent for applying mouse genetics to dissect viral entry and validate the role of scavenger receptor type B class 1, a molecule that is being considered as a novel antiviral drug target, for HCV uptake in a living animal," says Charles M. Rice, Maurice R. and Corinne P. Greenberg Professor and head of the Laboratory of Virology and Infectious Disease at Rockefeller. Rice also is executive and scientific director of the Center for the Study of Hepatitis C, an interdisciplinary center established jointly by The Rockefeller University, NewYork-Presbyterian Hospital and Weill Cornell Medical College.

Worldwide at least 130 million people are chronically infected with HCV, which poses a risk of severe liver injury and liver cancer. Current treatments are only partially effective and have considerable side effects, and a vaccine against hepatitis C does not exist.

"The global HCV epidemic mandates the development of more effective therapeutics including a vaccine," says Ploss. "This mouse model is a first step toward a platform that effectively serves this purpose."


Contact: Joseph Bonner
Rockefeller University

Related medicine news :

1. Scientists unlock potential of frog skin to treat cancer
2. The New York Stem Cell Foundation awards fellowships to 7 innovative stem cell scientists
3. UCSB scientists discover new direction in Alzheimers research
4. Indiana University neuroscientists map a new target to wipe pain away
5. NIH scientists reactivate immune cells exhausted by chronic HIV
6. Scientists identify overactive genes in aggressive breast cancers
7. Tie Between Biomarkers, Disease Often Overstated, Scientists Say
8. California scientists discover how vitamins and minerals may prevent age-related diseases
9. Scientists Discover Ultra-Bad Cholesterol
10. 3 renowned scientists recruited for cancer, physics and chemistry research at Rice
11. Scientists Appear One Step Closer to Reading Minds
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: